Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1
Immunogen
A phosphospecific peptide corresponding to residues surrounding tyrosine 1222 of human HER2 was used as an immungen. This antibody detects HER2 phosphorylated at tyrosine 1222.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
HER2 (ErbB2, epidermal growth factor receptor 2) is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of HER2 can be activated without ligand if it is overexpressed, and by association with other HER proteins (2). Overexpression of HER2 is detected in almost 40% of human breast cancers (3). HER2 is considered one of the major targets for the treatment of breast cancer and other carcinomas. Binding of c-Cbl ubiquitin ligase to Tyr1112 of HER2 leads to poly-ubiquitination of HER2 and enhances its degradation (4). Similar to other growth factors, HER2 exhibits intrinsic protein tyrosine kinase activity and undergoes autophosphorylation (Y1023, Y1248, Y1139, and Y1222). A phosphorylation at tyrosine 1139 has been identified to induce the binding of Src to HER2, leading to HER2 activation of Stat3 alpha (5).
Related Pathway
Adherens junction
Focal Adhesion
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
